Peri-Implantitis Versus Mucositis: When to Treat, When to Refer, When to Explant

Definitions applied to the data:

• Peri-implant mucositis: BOP and/or suppuration with no progressive bone loss beyond initial remodeling.
• Peri-implantitis: BOP and/or suppuration plus progressive bone loss beyond initial remodeling, often with increased probing depth.

This case is peri-implantitis:

• There is 1.8 mm of bone loss compared with the 1-year baseline - that is progressive loss beyond the expected early remodeling, and it is the defining criterion. A single radiograph cannot establish progression; the comparison to the 1-year film is what makes the diagnosis.
• The distal 5 mm pocket with a saucer-shaped defect and BOP is consistent with a localized peri-implantitis lesion.
• No suppuration and no mobility are reassuring - the implant is likely still integrated, but that does not downgrade the diagnosis.

Confounders to address:

• Smoking (10/day) and HbA1c 7.8% are both risk factors for progression; they do not change the diagnosis but change the prognosis and the treatment plan.
• 3 years without maintenance is the likely proximate cause.
• Confirm the 1-year radiograph is comparable (same angle, same sensor) before calling it progression; if not, obtain a new standardized film and compare at 3–6 months.

Key teaching point: The exam will try to get you to call this mucositis because there is no suppuration and no mobility. The bone-loss comparison overrides those findings.

Non-surgical phase first (all peri-implantitis starts here):

• Mechanical debridement of the implant surface (titanium or plastic curettes, ultrasonic with a non-metal tip) plus adjunctive antiseptic (chlorhexidine) and, where appropriate, local or systemic antibiotics - though evidence for routine systemic antibiotics is weak and should be reserved for acute infection or systemic risk.
• Restorative assessment: remove and re-torque the crown/provisional; check for submucosal cement (a common cause of localized distal bone loss), residual cement, or a poorly fitting restoration. If cement is present, retrieve it.
• Occlusal check: rule out fremitus or a heavy distal contact.
• Risk-factor modification: smoking cessation counseling, referral to the physician for glycemic control (HbA1c 7.8% is above target), and enrollment in 3-month maintenance.
• Re-evaluate at 6–8 weeks with probing, BOP, and a standardized radiograph.

Escalation if non-surgical fails (persistent BOP, pocket ≥5 mm, continued bone loss):

• Surgical access with surface decontamination (air-abrasive, citric acid, or laser - evidence is mixed; the key is debridement and access), with or without resection or regeneration depending on defect morphology (contained defects do better with regeneration).
• Referral to a periodontist or oral surgeon is appropriate when: the defect is inaccessible, the patient cannot tolerate surgery, the implant is in the aesthetic zone with a complex defect, or the clinician lacks the surgical armamentarium.

Explantation thresholds:

• Implant mobility, a defect that leaves insufficient bone to support the implant, a non-restorable position, or failure of repeated surgical therapy. In this case, with no mobility and a localized 1.8 mm defect, explantation is not indicated now.

Response:

• Explain the difference between mucositis (reversible inflammation) and peri-implantitis (progressive bone loss). Antibiotics and rinses treat the inflammation but do not remove the biofilm from the implant surface, which is the cause. Without mechanical debridement and risk-factor control, the bone loss will continue.
• Be honest about the evidence: adjunctive antibiotics are not a substitute for debridement, and overuse carries resistance and systemic risk.
• Connect the plan to his risk factors: smoking and HbA1c 7.8% roughly double the risk of progression; maintenance every 3 months is not optional in his case.
• Offer a clear decision: proceed with debridement + maintenance now, or accept the risk of continued bone loss and possible implant loss. Do not frame it as 'antibiotics vs. nothing' - frame it as 'active treatment vs. monitored decline.'

Documentation:

• Diagnosis (peri-implantitis, localized distal, 1.8 mm progressive bone loss vs. 1-year baseline).
• Risk factors (smoking 10/day, HbA1c 7.8%, 3-year maintenance gap).
• Treatment rendered and the re-evaluation date.
• The informed refusal if he declines, including the specific risks he accepted (progression, implant loss, need for explantation and grafting).
• A signed note that he was advised to quit smoking and to see his physician about glycemic control.